CRISPR Therapeutics counsel sells 10,400 shares

Kasinger's sales were made under a Rule 10b5-1 plan adopted on May 6, 2026.

Available on EDGAR 09/24/2026 - 05:36 PM EDT Accepted by SEC EDGAR 09/24/2026 - 05:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share, acquired 10,400 shares, and sold 10,400 shares at a weighted average price of $60.2365 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026. The option transaction reported 83,232 shares following the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,400 shares ($485K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Sold 10,400 shs ($626K)

Approx. gross sale proceeds $626K

Approx. exercise cost $142K

Approx. pre-tax spread $485K

Share of Position Sold 9.9%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F4	10,400	$0.00	$0.00
Exercise	Common Shares F1	10,400	$13.62	$142K
Sale	Common Shares F2, F3	10,400	$60.2365	$626K

Holdings After Transaction: Stock Option (Right to Buy) — 83,232 options (Direct); Common Shares — 94,784 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 93,632 to 83,232 options (Direct); Common Shares, 94,784 to 94,784 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

1. F1. Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Key Figures

Options exercised: 10,400 options Exercise price: $13.62 per share Common shares acquired: 10,400 shares +3 more

6 metrics

Options exercised 10,400 options September 22, 2026

Exercise price $13.62 per share Options exercised September 22, 2026

Common shares acquired 10,400 shares September 22, 2026

Common shares sold 10,400 shares September 22, 2026

Weighted average sale price $60.2365 per share Sale on September 22, 2026

Shares following option exercise 83,232 shares Reported following the September 22, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy)

3 terms

Rule 10b5-1 trading plan regulatory

"Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRSP shares did General Counsel and Secretary James R. Kasinger sell, and at what price?

James R. Kasinger sold 10,400 common shares on September 22, 2026, at a weighted average price of $60.2365 per share. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive.

How many CRSP options did James R. Kasinger exercise, and at what price?

He exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share. The option transaction reported 83,232 shares following the exercise.

When were the CRSP options originally granted, and what was their vesting schedule?

The option was granted on May 31, 2017, with respect to 123,000 common shares. The footnote states that 25% shall vest on May 31, 2018, and the remaining 75% shall vest monthly thereafter for 36 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/22/2026		M		10,400	A	$13.62	105,184(1)	D
Common Shares	09/22/2026		S(2)		10,400	D	$60.2365(3)	94,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.62	09/22/2026		M			10,400	(4)	05/31/2027	Common Shares	10,400	$0.00	83,232	D

Explanation of Responses:

1. Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)